The issue at the center of this recall, which includes both the HeartMate II and HeartMate 3 LVAD, is the gradual buildup of biological materials. This can impact the device's performance, creating a heightened risk of injury or death.
CEO William Thorwarth, MD, speaks at ACR's 2023 Annual Meeting in D.C.
Source
ACR
UPDATED: As part of its drive to balance the budget, ACR also is reviewing “all programs and areas for potential savings," leaders told attendees at the organization's annual meeting.
Lawmakers held a hearing on this topic April 11, titled “Bolstering Chronic Care through Medicare Physician Payment," featuring testimony multiple medical specialty societies.